Studies found on by a search of: dipg

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG


Condition:   Brain Tumor
Interventions:   Device: Exablate;   Drug: Doxorubicin
Sponsor:   InSightec
Not yet recruiting

131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma


Condition:   DIPG
Interventions:   Drug: 131I-Omburtamab;   Device: Convention Enhanced Delivery
Sponsors:   Y-mAbs Therapeutics;   Labcorp Drug Development Inc;   Invicro
Not yet recruiting

A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)


Conditions:   Diffuse Intrinsic Pontine Glioma;   Diffuse Midline Glioma, H3 K27M-Mutant
Interventions:   Drug: BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance;   Drug: BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
Sponsors:   Bexion Pharmaceuticals, Inc.;   CTI Clinical Trial and Consulting Services

HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers


Conditions:   DIPG;   Brain Tumor, Pediatric, Recurrent;   Brain Tumor, DIPG;   Radiation Toxicity;   Radiation Exposure;   Brain Tumor, Pediatric
Intervention:   Other: This study does not include an intervention.
Sponsors:   University of Calgary;   University of Toronto;   Université de Montréal;   University of Ottawa;   Western University, Canada;   McMaster University;   Alberta Children's Hospital;   Stollery Children's Hospital;   British Columbia Children's Hospital;   CancerCare Manitoba;   Children's Hospital of Eastern Ontario;   The Hospital for Sick Children;   McMaster Children's Hospital;   Children's Hospital Medical Center, Cincinnati;   St. Justine's Hospital;   Montreal Children's Hospital of the MUHC;   IWK Health Centre;   Janeway Children's Health and Rehabilitation Centre;   Princess Margaret Hospital, Canada;   London Health Sciences Centre;   The Ottawa Hospital;   CHU de Quebec-Universite Laval

Nimotuzumab in Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children


Condition:   Diffuse Intrinsic Pontine Glioma
Intervention:   Drug: Nimotuzumab+CRT(concurrent IMRT and TMZ)
Sponsor:   Biotech Pharmaceutical Co., Ltd.

A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma


Condition:   DIPG
Interventions:   Drug: Bevacizumab Injection;   Radiation: Ultra-low-dose RT
Sponsor:   Tata Memorial Centre

A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)


Conditions:   Diffuse Intrinsic Pontine Glioma;   Malignant Glioma of Brain;   High Grade Glioma;   Bithalamic High Grade Glioma;   Brainstem Glioma;   Glioblastoma;   Anaplastic Astrocytoma
Interventions:   Drug: ribociclib;   Drug: Everolimus
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Novartis
Active, not recruiting

Molecular Profiling for Individualized Treatment Plan for DIPG


Condition:   Diffuse Intrinsic Pontine Glioma (DIPG)
Interventions:   Other: Specialized tumor board recommendation;   Radiation: Standard radiation therapy
Sponsors:   University of California, San Francisco;   Translational Genomics Research Institute

Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma


Condition:   DIPG
Intervention:   Biological: MDV9300
Sponsor:   Hadassah Medical Organization
Unknown status

Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).


Condition:   Diffuse Intrinsic Pontine Glioma (DIPG)
Intervention:   Drug: Melphalan hydrochloride
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Solving Kids' Cancer